This potent anti-cancer effect involves the induction of tumor cell death and the conversion of immunosuppressive tumors to immunogenic and tumoricidal microenvironments, accompanied by the augment of IFNs and pro-inflammatory cytokines, resulting in the enhanced recruitment of CD8+ T cells and NK cells, activation of DCs, and reduced populations of immunosuppressive cells (M2-like TAM and MDSCs). The gene discussed is CD8A; the disease is cancer.